Us2.v2 vs ElucidVivo A.3
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors. Us2.v2 automates the interpretation of echocardiograms to assess overall heart function and detect various cardiac diseases, whereas ElucidVivo A.3 provides quantitative analysis of arterial plaque composition from CT angiography to aid in atherosclerosis patient stratification. While both contribute to cardiovascular care, they utilize different imaging modalities and address distinct diagnostic focuses within cardiology.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Us2.v2 integrates seamlessly with existing PACS, CVIS, or EMR systems (HL7 and DICOM SR supported) to automate echocardiogram interpretation, delivering structured reports with measurements and disease detection for conditions like cardiac amyloidosis, heart failure, and valvular disease. ElucidVivo A.3 integrates with PACS/EMR systems to provide quantitative analysis of arterial plaque composition from CT angiography, aiding in atherosclerosis patient stratification and optimizing treatment decisions by visualizing plaque characteristics and deriving FFRct.
Us2.v2 offers 100% AI automation with explainable AI, providing transparent visual overlays and editable outputs, and has demonstrated good agreement with expert clinicians in studies for parameters like pulmonary hypertension and severe aortic stenosis. ElucidVivo A.3 objectively quantifies plaque components like Lipid-Rich Necrotic Core (LRNC) from CT images, with its plaque analysis validated against ground-truth histology, and its FFRct derivation has shown high accuracy compared to invasive FFR.
Us2.v2 is designed for 100% AI automation, eliminating manual frame selection and annotation, which implies a reduced learning curve and aims to streamline workflow by reducing reporting time by up to 70%. While ElucidVivo A.3 provides detailed quantitative analysis and 3D visualizations, its user interface follows typical clinical workflow patterns, suggesting a design intended to facilitate clinician use.
Us2.v2 significantly reduces reporting time by up to 70% and increases daily scan throughput, with automated reports generated in seconds, leading to faster diagnosis. ElucidVivo A.3 optimizes treatment decisions by providing detailed plaque characteristics and FFRct, aiding in stratifying atherosclerosis patients and potentially improving long-term patient management.
Us2.v2 is specialized for cardiology, automating echocardiogram analysis and reporting, and is compatible with any ultrasound manufacturer, making it suitable for echo labs across multiple sites. ElucidVivo A.3 serves cardiology, radiology, and vascular surgery by providing quantitative plaque analysis from CT angiography, which supports different departmental needs for atherosclerosis assessment and treatment planning.